DAMORA THERAPEUTICS INC (DMRA) Fundamental Analysis & Valuation

NASDAQ:DMRA • US36322Q2066

Current stock price

25.5 USD
+0.75 (+3.03%)
At close:
25.5 USD
0 (0%)
After Hours:

This DMRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. DMRA Profitability Analysis

1.1 Basic Checks

  • In the past year DMRA has reported negative net income.
  • DMRA had a negative operating cash flow in the past year.
  • DMRA had negative earnings in each of the past 5 years.
  • DMRA had a negative operating cash flow in each of the past 5 years.
DMRA Yearly Net Income VS EBIT VS OCF VS FCFDMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • DMRA has a Return On Assets of -80.54%. This is in the lower half of the industry: DMRA underperforms 69.51% of its industry peers.
  • DMRA has a Return On Equity (-87.29%) which is in line with its industry peers.
Industry RankSector Rank
ROA -80.54%
ROE -87.29%
ROIC N/A
ROA(3y)-102%
ROA(5y)-86.51%
ROE(3y)-113.78%
ROE(5y)-97.04%
ROIC(3y)N/A
ROIC(5y)N/A
DMRA Yearly ROA, ROE, ROICDMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • DMRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMRA Yearly Profit, Operating, Gross MarginsDMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. DMRA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, DMRA has more shares outstanding
  • DMRA has less shares outstanding than it did 5 years ago.
  • DMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DMRA Yearly Shares OutstandingDMRA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
DMRA Yearly Total Debt VS Total AssetsDMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • DMRA has an Altman-Z score of 43.82. This indicates that DMRA is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 43.82, DMRA belongs to the top of the industry, outperforming 94.17% of the companies in the same industry.
  • DMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 43.82
ROIC/WACCN/A
WACCN/A
DMRA Yearly LT Debt VS Equity VS FCFDMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 12.98 indicates that DMRA has no problem at all paying its short term obligations.
  • DMRA has a better Current ratio (12.98) than 86.99% of its industry peers.
  • DMRA has a Quick Ratio of 12.98. This indicates that DMRA is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 12.98, DMRA belongs to the best of the industry, outperforming 86.99% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.98
Quick Ratio 12.98
DMRA Yearly Current Assets VS Current LiabilitesDMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DMRA Growth Analysis

3.1 Past

  • DMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.73%, which is quite impressive.
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.19% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.46%
EPS Next 2Y38.53%
EPS Next 3Y23.8%
EPS Next 5Y17.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMRA Yearly Revenue VS EstimatesDMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2031 2032 2033 200M 400M 600M
DMRA Yearly EPS VS EstimatesDMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

1

4. DMRA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DMRA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DMRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMRA Price Earnings VS Forward Price EarningsDMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMRA Per share dataDMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DMRA's earnings are expected to grow with 23.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.53%
EPS Next 3Y23.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMRA Dividend Analysis

5.1 Amount

  • No dividends for DMRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DMRA Fundamentals: All Metrics, Ratios and Statistics

DAMORA THERAPEUTICS INC

NASDAQ:DMRA (4/27/2026, 8:00:01 PM)

After market: 25.5 0 (0%)

25.5

+0.75 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-06
Inst Owners7.95%
Inst Owner Change0.84%
Ins Owners0.99%
Ins Owner Change100%
Market Cap1.54B
Revenue(TTM)N/A
Net Income(TTM)-209.84M
Analysts85.45
Price Target46.07 (80.67%)
Short Float %1.88%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)13.04%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-30.53%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.4
P/tB 6.4
EV/EBITDA N/A
EPS(TTM)-17.62
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS3.99
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -80.54%
ROE -87.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-102%
ROA(5y)-86.51%
ROE(3y)-113.78%
ROE(5y)-97.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.98
Quick Ratio 12.98
Altman-Z 43.82
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%151.63%
EPS Next Y94.46%
EPS Next 2Y38.53%
EPS Next 3Y23.8%
EPS Next 5Y17.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-116.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-930.83%
EBIT Next 3Y-123.84%
EBIT Next 5YN/A
FCF growth 1Y63.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.88%
OCF growth 3YN/A
OCF growth 5YN/A

DAMORA THERAPEUTICS INC / DMRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DAMORA THERAPEUTICS INC (DMRA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DMRA.


What is the valuation status of DAMORA THERAPEUTICS INC (DMRA) stock?

ChartMill assigns a valuation rating of 1 / 10 to DAMORA THERAPEUTICS INC (DMRA). This can be considered as Overvalued.


What is the profitability of DMRA stock?

DAMORA THERAPEUTICS INC (DMRA) has a profitability rating of 0 / 10.


What is the financial health of DAMORA THERAPEUTICS INC (DMRA) stock?

The financial health rating of DAMORA THERAPEUTICS INC (DMRA) is 9 / 10.